Moreover, cilengitide is reported to overcome the resistance of HER2-positive breast cancer to trastuzumab by targeting ITGβ3 to inhibit the activity of Hh pathway and the transcription of EMT-TFs (203). Here, ERBB2 is linked to breast cancer.